News Quantified

CRVS – corvus pharmaceuticals, inc. (US:NASDAQ)

Stock Stats

News Stats

Order Stats

News

Individual investors account for 50% of Corvus Pharmaceuticals, Inc.'s (NASDAQ:CRVS) ownership, while private equity firms account for 16% [Yahoo! Finance]

Corvus Pharmaceuticals Announces Publication of Biochemistry and Preclinical Data Demonstrating Potential of ITK Inhibition with Soquelitinib as a Novel Approach to Modulate Tumor Immunity [Yahoo! Finance]

Corvus Pharmaceuticals Announces Publication of Biochemistry and Preclinical Data Demonstrating Potential of ITK Inhibition with Soquelitinib as a Novel Approach to Modulate Tumor Immunity

Corvus (CRVS) is on the Move, Here's Why the Trend Could be Sustainable [Yahoo! Finance]

Corvus Pharmaceuticals Announces New Preclinical Data Highlighting Potential of Soquelitinib to Treat Systemic Sclerosis [Yahoo! Finance]

2.1%

MISS

4.4%

BEAT

-12.0%

IN-LINE

Form 10-Q Corvus Pharmaceuticals, For: Sep 30

Form 8-K Corvus Pharmaceuticals, For: Nov 12

Form 8-K Corvus Pharmaceuticals, For: Oct 22

Top News Gainers

7/2 Form SC 13D/A Corvus Pharmaceuticals, Filed by: ORBIMED ADVISORS LLC 25.5%

7/1 Form 4 Corvus Pharmaceuticals, For: Jun 27 Filed by: ORBIMED ADVISORS LLC 21.0%

8/8 Form 4 Corvus Pharmaceuticals, For: Aug 06 Filed by: MILLER RICHARD A MD 20.7%

11/4 Corvus Pharmaceuticals to Webcast Investor & Analyst Event on November 8, 2019 12.4%

3/20 Form EFFECT Corvus Pharmaceuticals, 12.3%

12/16 Form 4 Corvus Pharmaceuticals, For: Dec 12 Filed by: Hunt Daniel W. 10.6%

11/14 Form 4 Corvus Pharmaceuticals, For: Nov 12 Filed by: MILLER RICHARD A MD 9.9%

4/15 Form DEF 14A Corvus Pharmaceuticals, For: Jun 09 7.3%

10/17 Corvus Pharmaceuticals to Provide Business Update and Report Third Quarter 2019 Financial Results on October 29, 2019 6.7%

5/9 Q1/2019 3/31/2019 EPS -0.400 ZacksConsensus -0.400 ActVsEst 0.000 - In-Line 6.1%

Top News Decliners

4/30 Form 10-Q Corvus Pharmaceuticals, For: Mar 31 -13.7%

3/5 Q4/2019 12/31/2019 EPS -0.380 ZacksConsensus -0.330 ActVsEst (0.050) - Miss -12.5%

3/20 Form 424B5 Corvus Pharmaceuticals, -11.4%

7/15 Corvus Pharmaceuticals Inc (NASDAQ: CRVS) was upgraded by analysts at Zacks Investment Research from a "sell" rating to a "hold" rating. -10.3%

11/12 Form 8-K Corvus Pharmaceuticals, For: Nov 08 -9.3%

2/13 Corvus Pharmaceuticals Presents Updated Clinical Data from its Phase 1b/2 Clinical Trial of Ciforadenant at the 2020 American Society of Clinical Oncology’s Genitourinary Cancers Symposium -9.3%

8/4 Corvus Pharmaceuticals, Inc. (CRVS) CEO Richard Miller on Q2 2019 Results - Earnings Call Transcript [Seeking Alpha] -9.2%

11/8 Corvus Pharmaceuticals Presents Updated Data from CPI-006 Phase 1/1b Clinical Trial at 2019 Society for Immunotherapy of Cancer (SITC) Annual Meeting -9.2%

12/31 Corvus Pharmaceuticals Inc (NASDAQ: CRVS) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. -8.3%

9/12 Corvus Pharmaceuticals Inc (NASDAQ: CRVS) had its "buy" rating re-affirmed by analysts at Mizuho. They now have a $7.00 price target on the stock. -8.2%

Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies

If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.

Click Here To Register For The Live Online Workshop

In short, News Quantified specializes in matching financial news with market data. We've analyzed 10s of millions of news events and know exactly which ones have an outsized impact on stock prices. So every single time a news item is released we know exactly what the average effect will be on a particular stock.

Latest Posts

Trading the Google Earnings Announcement: A Strategic Preview

Earnings Week Wrap-up and Takeaways

Earnings Season: Q3 Review, Q4 Kickoff – Morgan Stanley, Bank of America, Goldman Sachs, Netflix

Guerrilla Learning Opportunity: Wealth365 Conference Featuring News Quantified Founder and Much More

The Smart Way to Ten Minutes Per Day